Intech Investment Management LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 13.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,818 shares of the medical research company’s stock after selling 4,341 shares during the period. Intech Investment Management LLC’s holdings in Amgen were worth $11,304,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of AMGN. BlackRock Inc. boosted its holdings in Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after buying an additional 2,261,544 shares during the period. State Street Corp grew its stake in Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after buying an additional 11,656,755 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Amgen by 12.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock valued at $1,952,156,000 after acquiring an additional 605,928 shares during the period. Bank of America Corp DE bought a new stake in Amgen during the 2nd quarter valued at $1,831,903,000. Finally, Amundi raised its holdings in Amgen by 15.2% during the 2nd quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock valued at $1,408,715,000 after acquiring an additional 512,883 shares during the period. Institutional investors own 76.50% of the company’s stock.
Amgen Price Performance
Shares of NASDAQ:AMGN opened at $462.32 on Tuesday. The company has a 50 day moving average of $425.81 and a 200 day moving average of $381.77. The stock has a market cap of $250.07 billion, a P/E ratio of 26.82, a P/E/G ratio of 3.25 and a beta of 0.43. Amgen Inc. has a 12 month low of $312.39 and a 12 month high of $483.99. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60.
Amgen (NASDAQ:AMGN – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The business had revenue of $10.37 billion for the quarter, compared to analysts’ expectations of $10.07 billion. During the same period in the prior year, the company posted $5.64 EPS. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Amgen Inc. will post 23.37 EPS for the current fiscal year.
Amgen Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. Amgen’s dividend payout ratio is presently 58.47%.
Analysts Set New Price Targets
Several research firms have issued reports on AMGN. UBS Group increased their target price on Amgen from $470.00 to $530.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Mizuho lifted their price target on Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research report on Tuesday, August 18th. Weiss Ratings upgraded Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Truist Financial boosted their price objective on Amgen from $380.00 to $398.00 and gave the company a “hold” rating in a research note on Wednesday, November 4th. Finally, Wells Fargo & Company increased their price objective on Amgen from $430.00 to $460.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $425.69.
Check Out Our Latest Stock Analysis on Amgen
About Amgen
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Read More
- Five stocks we like better than Amgen
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
